Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA, Smit E, Carpeño Jde C, Leśniewski-Kmak K, Aerts J, Kraaij K, Visseren-Grul C, Dyachkova Y, Taipale K, Girvan A, Moro-Sibilot D. Schnabel PA, et al. Among authors: taipale k. Lung Cancer. 2012 Dec;78(3):263-9. doi: 10.1016/j.lungcan.2012.09.001. Epub 2012 Oct 4. Lung Cancer. 2012. PMID: 23040326 Clinical Trial.
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Taipale K, Girvan AC, Visseren-Grul C, Schnabel PA. Moro-Sibilot D, et al. Among authors: taipale k. Lung Cancer. 2015 May;88(2):215-22. doi: 10.1016/j.lungcan.2015.02.011. Epub 2015 Feb 21. Lung Cancer. 2015. PMID: 25748103
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study.
Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, Soldatenkova V, Visseren-Grul C, Zanotti G, Taipale K, Moro-Sibilot D. Vergnenegre A, et al. Among authors: taipale k. Curr Med Res Opin. 2012 Aug;28(8):1253-62. doi: 10.1185/03007995.2012.703133. Epub 2012 Jul 5. Curr Med Res Opin. 2012. PMID: 22697276
Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study.
Gold R, Schmidt S, Deisenhammer F, Motte J, Richter N, Taipale K, Salmen HC, Bohland C, Schirduan K. Gold R, et al. Among authors: taipale k. Ther Adv Neurol Disord. 2024 Apr 13;17:17562864241241382. doi: 10.1177/17562864241241382. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38616781 Free PMC article.
Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
Klehmet J, Begus-Nahrmann Y, Taipale K, Niemczyk G, Rehberg-Weber K. Klehmet J, et al. Among authors: taipale k. Ther Adv Neurol Disord. 2023 Dec 15;16:17562864231214041. doi: 10.1177/17562864231214041. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 38107443 Free PMC article.
29 results